Extended Depth-Of-Focus Intraocular Lens Implantation In Eyes With Retinal Pathology

To evaluate the visual outcomes of the implantation of extended depth of focus (EDOF) intraocular lens (IOL) in patients with macular pathology

Ophthalmology department, Hillel Yaffe medical center, Hadera, Israel.

A retrospective case series of all patients with macular pathology who underwent cataract surgery and were implanted with either nondiffractive wavefront-shaping EDOF IOL (AcrySof IQ Vivity) or refractive aspheric hybrid EDOF IOL (LUCIDIS) over a 2.5 years period.

Corrected distance visual acuity (CDVA), distance-corrected near visual acuity, defocus curve, contrast sensitivity, central foveal thickness, VF-14 questionnaire results, and quality of life where available were analyzed.

A total of 22 eyes of 15 patients were included in this study (60% male). Of 22 eyes that had macular pathology, 13 (60%) had epiretinal membrane (ERM), 4 (18%) had submacular drusen, 3(14%) had combined ERM and submacular drusen and 2 eyes (9%) had ERM and vitreomacular adhesions. Two patients developed psuedophakic macular edema. Mean patient preoperative CDVA was logMAR 0.45. Postoperative monocular CDVA was logMAR 0.20. Eyes achieving CDVA of Snellen 6/6–6/12 showed contrast sensitivity within the normal range. On postoperative VF-14 questionnaire, patients reported minimal visual impairment. A majority of patients (90%, n=20) were satisfied with the improvement in quality of life postoperatively.

The EDOF IOL lens implantation in patients with mild macular pathology is safe and resulted in a good patient satisfaction with a mild limitation in contrast sensitivity and improvement in quality of life.